- Company
- [Photo]“Dismissal is a murder” Sanofi Labor Union protests
- by An, Kyung-Jin Jul 29, 2020 06:30am
- On July 27, the Sanofi-Aventis Korea Labor Union Chapter of Federation of Korean Chemical Workers' Unions (FKCU) was gathered in front of the company’s Seoul headquarters to denounce the management’s unfair disciplinary action Sanofi-Aventis Korea’s Disciplinary Committee meeting was scheduled in the afternoon to deliberate a salesp
- Policy
- Tecentriq combo wins coverage as first-line on NSCLC
- by Lee, Hye-Kyung Jul 28, 2020 06:37am
- Roche Korea’s Tecentriq (atezolizumab) is to receive coverage on treating patients with non-small cell lung cancer (NSCLC) as a first-line treatment. South Korea’s Health Insurance Review and Assessment Service (HIRA) disclosed the revised notice on anticancer treatment with the said update, which would accept public opinion on the rev
- Company
- Generics for Betmiga competition gets fierce
- by Kim, Jin-Gu Jul 28, 2020 06:37am
- Full-fledged competition began in the generic market of “Betmiga (Mirabegron),” which has annual outpatient prescriptions of &8361;65 billion. Hanmi and Chong Kun Dang, which received generic for exclusivity, recently released generics. The two companies plan to focus on expanding the market until February next year when the trial perio
- Policy
- Copayment of Choline alfoscerate other than dementia is 80%
- by Kim, Jung-Ju Jul 28, 2020 06:36am
- The government's commitment to the re-evaluation of the already listed Choline alfoscerate was clear, and the results of the re-evaluation of Choline alfoscerate, which had strong social demands, eventually ended up maintaining the benefits only for dementia. The government left only the task of applying the revision after making an admi
- Policy
- Multiple myeloma drug Farydak was revoked after approval
- by Lee, Jeong-Hwan Jul 28, 2020 06:33am
- Farydak (Panobinostat), which can be used for patients who have failed to administer Velcade (Bortezomib), was revoked after three years of domestic marketing approval. There are many domestically licensed multiple myeloma medications, and the track listings, such as Risk-Sharing Agreement (RSA), have had an effect on the cancellation of t
- Company
- MFDS collects acetaminophen to confirm impurity
- by Chon, Seung-Hyun Jul 28, 2020 06:33am
- The South Korean government is initiating an investigation on impurity contamination in an active pharmaceutical ingredient (API), acetaminophen. As the risk of impurity contamination in API manufactured by a Chinese manufacturer was raised recently, the government started proactively collecting and testing the API used in Korea. If the wid
- Policy
- Government “Concerned of COVID-19 vaccine monopolization”
- by Lee, Hye-Kyung Jul 27, 2020 09:41am
- The South Korean government says it is closely following up with international sources to timely access the COVID-19 treatment and vaccine. At a regular briefing on July 23, Kwon Jun-wook, a deputy director of the Central Disease Control Headquarters, said “The disease control authority is paying a close attention to the global cases of
- Policy
- Betmiga’s price is temporarily on hold due to lawsuits
- by Kim, Jung-Ju Jul 27, 2020 09:41am
- Betmiga products by Astellas Korea, which are at risk of dropping more than 30%, are temporarily on hold due to lawsuits filed by Astellas. The court decided to keep the price before the adjustment for the time being until the ruling of Betmiga trial is over as requested by the company. The Seoul Administrative Court decided to extend
- Policy
- Lipiodol's suspension of price cuts has been extended
- by Kim, Jung-Ju Jul 27, 2020 09:41am
- The court decided to extend the suspension of drug price cuts against Guerbet Korea's Lipiodol Ultra Liquid (Iodized oil, 12.8g/10mL). The court set the suspension period to 30 days from the date of the sentence of judgment in preparation for prolonged litigation. Seoul Administrative Court decided to suspend execution of a decision re
- Company
- MFDS to tighten up regulations on appetite suppressant
- by jung, sae-im Jul 27, 2020 06:31am
- The South Korean health authority drafted regulations preventing the abuse of psychoactive appetite suppressants. The draft contains high-level of regulations like adopting active substance designation system used in narcotics control, which can heavily impact the relevant industry. According to pharmaceutical industry sources on July 2
